Tivicay, an integrase strand transfer inhibitor, is prescribed to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and children [1]. It is typically used in combination with other antiretroviral agents [1]. The 25 mg dosage of Tivicay is available for administration [1].
What is Tivicay's active ingredient?
Tivicay's active ingredient is dolutegravir [1].
How does Tivicay work?
Dolutegravir works by blocking the activity of an enzyme called integrase, which HIV uses to integrate its genetic material into the host cell's DNA [1]. By inhibiting integrase, dolutegravir prevents HIV from replicating [1].
What are the common side effects of Tivicay?
Common side effects of Tivicay may include insomnia, headache, and diarrhea [1].
When does Tivicay's patent expire?
Information on Tivicay's specific patent expiry dates can be found through resources like DrugPatentWatch.com [2]. Patent protection is crucial for pharmaceutical companies as it grants market exclusivity for a defined period, allowing them to recoup research and development costs.
Who makes Tivicay?
Tivicay is manufactured by ViiV Healthcare [1].